Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab.

Emirova K, Volokhina E, Tolstova E, van den Heuvel B.

BMJ Case Rep. 2016 Feb 15;2016. pii: bcr2015213928. doi: 10.1136/bcr-2015-213928. Erratum in: BMJ Case Rep. 2016;2016. pii: bcr2015213928corr1. doi: 10.1136/bcr-2015-213928corr1.

2.

Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement.

Hu H, Nagra A, Haq MR, Gilbert RD.

Pediatr Nephrol. 2014 Jun;29(6):1103-6. doi: 10.1007/s00467-013-2709-z. Epub 2013 Dec 8.

PMID:
24317637
3.

Eculizumab in secondary atypical haemolytic uraemic syndrome.

Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M.

Nephrol Dial Transplant. 2017 Mar 1;32(3):466-474. doi: 10.1093/ndt/gfw453.

4.

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.

Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.

PMID:
26247170
5.

Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.

Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M.

Nephrology (Carlton). 2016 Mar;21(3):261-5. doi: 10.1111/nep.12582.

PMID:
26818219
6.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.

Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.

7.

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.

J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.

8.

Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.

Gately R, San A, Kurtkoti J, Parnham A.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:32-35. doi: 10.1111/nep.12938. Review.

PMID:
28176475
9.

Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.

Chua J, Paizis K, He SZ, Mount P.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:18-22. doi: 10.1111/nep.12935. Review.

PMID:
28176472
10.

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.

Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H.

J Nephrol. 2017 Feb;30(1):127-134. doi: 10.1007/s40620-016-0288-3. Epub 2016 Mar 19.

11.

Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.

Carter S, Hewitt I, Kausman J.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:7-10. doi: 10.1111/nep.12932. Review.

PMID:
28176479
12.

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.

Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.

13.

Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.

Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.

Transfus Apher Sci. 2016 Dec;55(3):357-362. doi: 10.1016/j.transci.2016.09.017. Epub 2016 Sep 30.

PMID:
27742267
14.

Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome.

Yamada Y, Abe R, Okano Y, Miyakawa Y.

Intern Med. 2017;56(9):1085-1088. doi: 10.2169/internalmedicine.56.7862. Epub 2017 May 1.

15.

Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.

Terano C, Ishikura K, Hamada R, Yoshida Y, Kubota W, Okuda Y, Shinozuka S, Harada R, Iyoda S, Fujimura Y, Hamasaki Y, Hataya H, Honda M.

Nephrology (Carlton). 2018 Jun;23(6):539-545. doi: 10.1111/nep.13054.

PMID:
28387984
16.

Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension.

Ohta T, Urayama K, Tada Y, Furue T, Imai S, Matsubara K, Ono H, Sakano T, Jinno K, Yoshida Y, Miyata T, Fujimura Y.

Pediatr Nephrol. 2015 Apr;30(4):603-8. doi: 10.1007/s00467-014-2975-4. Epub 2014 Oct 16.

PMID:
25318620
17.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
18.

Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection.

Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E.

BMJ Case Rep. 2017 Apr 26;2017. pii: bcr-2016-219065. doi: 10.1136/bcr-2016-219065.

19.

Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.

Krishnan AR, Siva B, Chakera A, Wong G, Wong D, Lim WH.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:28-31. doi: 10.1111/nep.12937. Review.

PMID:
28176477
20.

Can eculizumab be discontinued in aHUS?: Case report and review of the literature.

Sahutoglu T, Basturk T, Sakaci T, Koc Y, Ahbap E, Sevinc M, Kara E, Akgol C, Caglayan FB, Unsal A, Daha MR.

Medicine (Baltimore). 2016 Aug;95(31):e4330. doi: 10.1097/MD.0000000000004330. Review.

Supplemental Content

Support Center